da Costa Anaelle, Metais Thibaud, Mouthon Franck, Kerkovich Danielle, Charvériat Mathieu
Theranexus, Lyon, France.
Beyond Batten Disease Foundation, Austin, TX, USA.
Fundam Clin Pharmacol. 2021 Jun;35(3):539-551. doi: 10.1111/fcp.12634. Epub 2020 Dec 25.
TFEB is a mammalian transcription factor that binds directly to the CLEAR consensus sequence (5'-GTCACGTGAC-3') present in the regulatory regions of genes inducing autophagosome formation, autophagosome-lysosome fusion, hydrolase enzyme expression, and lysosomal exocytosis. By modulating these activities, TFEB coordinates on-demand control over each cell's degradation pathway. Thus, a nuclear signaling pathway regulates cellular energy metabolism through TFEB. Our growing understanding of the role of TFEB and CLEAR in the promotion of healthy clearance together with in vitro and in vivo preclinical findings in various animal models of disease supports the conclusion that the pharmacological activation of TFEB could clear toxic proteins to treat both rare and common forms of neurodegenerative disease.
TFEB是一种哺乳动物转录因子,它直接与诱导自噬体形成、自噬体-溶酶体融合、水解酶表达和溶酶体胞吐作用的基因调控区域中存在的CLEAR共有序列(5'-GTCACGTGAC-3')结合。通过调节这些活动,TFEB协调对每个细胞降解途径的按需控制。因此,一条核信号通路通过TFEB调节细胞能量代谢。我们对TFEB和CLEAR在促进健康清除方面作用的日益了解,以及在各种疾病动物模型中的体外和体内临床前研究结果支持这样的结论,即TFEB的药理学激活可以清除有毒蛋白质,以治疗罕见和常见形式的神经退行性疾病。